Anthem Biosciences Ltd.
NSE: ANTHEMAnthem Biosciences Ltd.: A 30-second snapshot
Anthem Biosciences (₹820.10) is a pharma-sector stock trading above both its 50-DMA (₹708.81) and 200-DMA (₹713.28) with a 3-month gain of 21.2%, yet its 5-year fundamentals show sustained deterioration: revenue down 15% and earnings down 25.8% over that span. The stock carries a trailing PE of 91.83, the highest in its 6-stock pharma peer group, against a quality score of 24 that ranks near the bottom of that same peer set.
P/E
91.8
Forward P/E
63.4
ROE
—
Debt / Equity
4.00
Profit Margin
+24.2%
Div. Yield
—
5Y ROE > 15%
4/5
5Y FCF > 0
3/5
Quality
40/100
News
8 headlines · 3 positive · 0 negative
Anthem Biosciences Schedules Board Meeting on May 19, 2026 to Approve FY26 Financial Results and Consider Final Dividend - scanx.trade
scanx.trade
Anthem Biosciences share price target 2026: Mutual funds raise stakes; Citi sees 17% upside after initiating coverage on pharma stock - MSN
MSN
Stocks to Buy: Citi projects 20% upside for a stock that Mutual Funds lapped up in March - CNBC TV18
CNBC TV18
Anthem Biosciences Share Price Target 2026: Mutual Funds raise stakes; Citi sees 17% upside after initiating coverage on pharma stock - ET Now
ET Now
Anthem Biosciences Avoids SEBI 'Large Corporate' Tag With ₹2.96 Cr Borrowing - Whalesbook
Whalesbook
Recent context
- ·Citi initiated coverage on Anthem Biosciences in April 2026, with a stated price target implying upside; this is a specific named-broker action representing the first institutional sell-side initiation in recent news flow.
- ·Mutual funds raised stakes in Anthem Biosciences in March–April 2026, as reported by multiple outlets, indicating institutional accumulation concurrent with the 3-month price rally.
- ·A board meeting on May 19, 2026 will consider FY26 full-year results and a final dividend; this is the first comprehensive annual earnings disclosure since the stock entered the news cycle, and the outcome will either validate or challenge the current valuation multiple.
Strengths
- +Profit margin of 24.2% is a meaningful absolute level for a pharma company, suggesting the business retains pricing power or cost discipline at the gross level despite top-line contraction.
- +FCF was positive in 3 of the available historical years, and ROE exceeded 15% in 4 of those years, indicating periods of capital efficiency within the longer-term decline.
- +Price is 15.7% above the 50-DMA and 14.9% above the 200-DMA, with a drawdown of only 6.1% from the 52-week high — the stock has shown strong near-term relative strength.
- +A board meeting is scheduled for May 19, 2026 to approve FY26 results and consider a final dividend, which could provide a near-term fundamental data point for reassessing the earnings trajectory.
Weaknesses
- −5-year earnings CAGR of -25.8% and revenue CAGR of -15% reflect a sustained multi-year contraction; the consistency score of 52 and these trends together indicate the deterioration spans multiple business cycles.
- −D/E of 3.997 with a rising debt trend imposes significant financial leverage on a business whose earnings have shrunk for 5 years; FCF was positive in only 3 of the years assessed.
- −Trailing PE of 91.83 ranks last (6 of 6) in the pharma peer group while quality score of 24 also ranks near the bottom (4 of 6 with available scores) — the stock commands the highest multiple against the weakest fundamental profile in the peer set.
- −RSI at 76.91 indicates the stock is in overbought territory after a 21.2% move in 3 months, with support levels 11–24% below current price (₹709.50, ₹677, ₹625.20).
Open questions
- ?Does the 5-year revenue and earnings contraction reflect a structural shift in Anthem Biosciences' business model, or does the FY26 results event signal a potential inflection in that trajectory?
- ?Given a D/E of nearly 4 and a rising debt trend, how does the company plan to service and reduce leverage if earnings growth does not recover materially?
- ?How much of the 21.2% 3-month rally is attributable to the Citi initiation and mutual fund flows rather than underlying fundamental improvement, and what happens to that premium if those catalysts fade?
- ?At a trailing PE of 91.83 — the highest in the pharma peer group — what level of earnings growth is embedded in the current price, and over what time horizon would the forward PE of 63.4 be achieved?
Peer comparison: Pharma
Ranks 4 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| ANTHEM | Anthem Biosciences Ltd.You're viewing | 91.8 | — | 24 |
| Industry avg | across 5 peers | 47.0 | +11.8% | 37 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 72.5 | — | 54 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 41.3 | — | 50 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 64.6 | — | 42 |
| CIPLA | Cipla Ltd. | 29.8 | +11.7% | 24 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 26.6 | +11.8% | 17 |
Technical state
Current price
₹820.10
SMA 50
₹708.81
SMA 200
₹713.28
RSI (14)
76.9 (overbought)
From 52w high
-6.1%
1Y return
—
3M return
+21.2%
50-DMA
Above
200-DMA
Above
Algorithmic support levels
Risk flags
- high5-year earnings CAGR of -25.8% alongside 5-year revenue CAGR of -15% reflects sustained multi-year contraction in core business scale, not an isolated quarterly miss.
- highD/E of 3.997 with a rising debt trend places heavy leverage on a business whose earnings have declined over the past 5 years; FCF was positive in only 3 of the available historical years.
- mediumQuality score of 24 ranks 4th of 6 pharma peers (last among comparables with scores); trailing PE of 91.83 is the highest in the peer set (ranked 6 of 6), placing maximum valuation weight on a deteriorating earnings trajectory.
- mediumRSI of 76.91 is in overbought territory; current price of ₹820.10 is 15.7% above the 50-DMA (₹708.81) and 14.9% above the 200-DMA (₹713.28), reflecting a sharp near-term extension from both moving averages.
- low1-year price change unavailable for ANTHEM and all 5 sector peers, limiting peer-relative momentum comparison. Analyst rating is also absent despite 7 analysts tracked.
Cross-section contradictions
- 5-year earnings have declined 25.8% and revenue 15% over the same period, yet the stock has gained 21.2% over the past 3 months — the near-term price appreciation diverges sharply from the multi-year fundamental trajectory.
- Trailing PE of 91.83 is the highest among the 6-stock peer group while the quality score of 24 is among the lowest — ANTHEM carries the steepest valuation premium in a peer set where its fundamental quality ranks near the bottom.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 25 Jun 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 15 May 2026 · rotates through NIFTY 500 every ~5 days